Determinants of trastuzumab deruxtecan response in metastatic breast cancer
The phase 2 DAISY trial suggests that HER2 expression is determinant of trastuzumab deruxtecan efficacy, but additional mechanisms may be involved
Day: August 7, 2023
The phase 2 DAISY trial suggests that HER2 expression is determinant of trastuzumab deruxtecan efficacy, but additional mechanisms may be involved